TABLE 2.

Reported mouse transgenic models of HER2/neu

Reference	Promoter	Gene	Phenotype
(Muller et al. 1988)	MMTV	neuT transgene	early, multiple mammary tumors by 3 months, short survival
(Bouchard et al. 1989)	MMTV	neuT transgene	mammary tumors stochastically, 5-10 months
(Guy et al. 1992)	MMTV	c-neu transgene	mammary tumors stochastically, 4-12 months, frequent lung metastases
(Andrechek et al. 2000)	endogenous	neuT knock-in	late mammary tumors, 12-17 months, with transgene amplification
(Weinstein et al. 2000)	murine neu	c-neu transgene	abnormal involution, focal mammary abnormalities in multiparous females, 1-2 years
(Weinstein et al. 2000)	murine neu	neuT transgene	abnormal involution, some late mammary tumors in multiparous females, 14 months
(Finkle et al. 2004)	MMTV	human HER2 transgene	multiple mammary tumors, 7 months, some lung mets
(Moody et al. 2002)	MMTV-rtTA / TetO	neuT transgene	rapid mammary tumors within 6 weeks and frequent lung mets, regress without dox
(Xie et al. 1998)	human Keratin 14	neuT transgene	severe hyperplastic lesions of skin, hair follicles, esophagus, perinatal lethal
(Bol et al. 1998)	bovine keratin 5	neuT transgene	severe hyperplastic lesions of skin, esophagus, papillomas, early death
(Kiguchi et al. 2000; Kiguchi et al. 2001)	bovine keratin 5	c-neu transgene	hyperplasia, allopecia, papillomas, skin carcinomas, biliary carcinomas, survive 6-12 months
(Xie et al. 1999)	K14-rtTA-TetRE	neuT transgene	rapid dox induction of hyperplastic lesions in skin, hair follicels, esophagus, regress without dox
(Li et al. 2006)	probasin	neuT transgene	prostatic intraepithelial neoplasia and invasive prostate cancer, 1-2 years